Wednesday, December 11, 2019

A NEW WEAPON AGAINST AN IMPORTANT FOE

Linda and her friend Janie
Amherst, Mass - I think
That's Linda's mom on the left

If you don’t read this link I won’t be indignant; it is dry and tough-going.  Nevertheless, I think the matter easily is important enough to blog about.  I’ve read it several times and Googled stuff I didn’t quite understand; here is what I got out of it.

There exists within us an important gene, KRAS. that is vital for the smooth and correct regulation of cell division.  In many types of cancer, mutated KRAS is a driving force, hence KRAS is classified as an oncogene.  One particular form of mutated KRAS, called G12C, codes for a protein that is present in a large percentage of cancers.  This has been known for many years but G12C has, for reasons far beyond my pay grade, been deemed “undruggable”.  Now an outfit called Amgen (AMGN; $234/share), one of the larger bio-research firms, announces that it has developed something that works against G12C; not only in mice, but in humans (Phase 1 trial underway}. The stuff they have concocted is called AMG 510. Nothing was said about AMG 510’s effect on ovarian cancer, but one can hope.

Almost daily I become newly awe-stricken by how complicated the processes that keep us alive and ticking are shown to be.  I would like to have been a cancer researcher rather than a geologist – but I doubt that I ever was smart enough!

Sunday, December 8, 2019

THE FRENCH MAKE GOOD WINE. and MEDICINE?


Linda, pretending to be inebriated
On our Norwegian cruise

I have long harbored mixed feelings about the French.  Not only do they eat all manner of slimy invertebrates and settle their important political issues by rioting; they refuse to use English under any circumstances.  However:  they do  turn out wonderful – if expensive – wines.  Now I report on something  else admirable – and French.
I have mentioned in several blogs how the science of applying immunotherapy to solid tumors has lagged.  Well, a French outfit named Transgene has taken up the challenge.  They have just received a go-ahead from our FDA for a Phase 1 clinical trial, which they will finance.  They apparently use a virus to deliver their juice to the tumor.  Every other aspect of the thing is far out of reach of my aged brain. 
Whatever, this must be big stuff because it was offered to the public by three separate agencies (below).  Read ‘em and tell me how this works.



Tuesday, December 3, 2019

A USEFUL SOURCE OF INFORMATION


LINDA TUSSLES WITH CAROLYN'S CAT

Good Lord!  I have been writing these blogs for over six years, relying on various sources – even a subscription to the NYTimes – for input.  Just this morning I got around to typing “ovarian cancer news” into Google – and found this:


I recommend that you all bookmark this web site, and consult it now and then.  I certainly will.

By the way, Google also will spit up a similar-sounding web name:


No doubt this outfit also has important OVCA news – but they make you pay for it.  I prefer to hand over my money to folks already on the field.  For instance, Fred Hutch: